Mar 22 |
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
|
Mar 17 |
30 Biggest Biotechnology Companies in the World
|
Mar 14 |
BeiGene gets FDA approval for esophageal cancer drug Tevimbra
|
Mar 14 |
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
|
Mar 14 |
UPDATE 1-US FDA approves BeiGene's esophageal cancer therapy
|
Mar 13 |
BeiGene gains as access to leukemia drug Brukinsa expands
|
Mar 13 |
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
|
Mar 13 |
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
|
Mar 8 |
BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
|
Mar 7 |
BeiGene gets FDA accelerated approval for Brukinsa for follicular lymphoma
|